EBS — Stock Film
STOCK FILMSCENE 1/11EBS · $5.08
Stock Expert AI presents
EBS
Emergent BioSolutions Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Emergent BioSolutions Inc. A quick introduction.

On the stock market since 2006, it operates in the world of health and science. It has 900 employees. Now — the numbers.

on the stock market since 2006
900 employees
$372.5M market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, $7 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 7%

This is an established company with proven profits.

WHERE DOES THE MONEY COME FROM?
95%Products
Products 95%Contracts and Grants 5%
95% of all revenue comes from a single line: Products.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

THE SALES TREND
Sales have been shrinking.

An average decline of 20% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.

$1.8B
2021
$1.1B
2022
$1B
2023
$1B
2024
$742.9M
2025
INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
65
strong

Clearly above the class average — a step short of the very top.

FINANCIAL STRENGTH
56
average

A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.

VALUATION
76
strong

Clearly above the class average — a step short of the very top.

GROWTH
48
weak

Clearly below the class average.

PRICE MOMENTUM
15
very weak

Clearly below the class average.

WORTH WATCHING

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

Growth: Sales growth trails the sector average.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 3 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit per sale, but shrinking8/10
WEAK SPOTS
The stock has lost its spark0/10
Executives aren’t buying3/10
WORTH WATCHING

Executive Buying: The trades send no strong signal of confidence.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 92% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
Delivers on expectations

It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.

2
THE BRIGHT SIDE · 2/2
Analysts’ target sits above today’s price

The average analyst price target is $10.0097% above today’s price.

1
THE RISKS · 1/2
A wildly swinging price

This stock swings about 2.3 times as much as the market average. Big rallies — and big drops — can both happen fast.

2
THE RISKS · 2/2
Sales are shrinking

Over the last 3 years, sales fell about 13% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, EBS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: EBS is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film